Summary

Overview
The global Addison’s disease market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Addison's crisis is a severe endocrine emergency immediate recognition and treatment are required. Patients diagnosed with this disease should be aware otherwise if not recognized and treated, the adrenal crisis can be fatal.
Various factors like Autoimmune, infections, Adrenal Hemorrhage, Adrenal Hemorrhage, Infiltration, and others cause Addison's disease. Mainly, Addison's disease is caused by an inability of the adrenal cortices to produce adequate adrenocortical hormones.
Furthermore, the global Addison disease market is driven by a rise in research and development, advancements in treatments, and rising healthcare expenditures in the countries.
Market Dynamics: Drivers
A Rise in the Prevalence & Awareness of Addison's Disease
The demand for the Addison’s disease market is driven by multiple factors. The rise in the prevalence of Addison’s disease is one of the key factors that drive the market to grow during the forecast period. Addison’s disease is a rare autoimmune disorder and the rise in the prevalence of this disease will increase the research and development of novel therapies which will help to boost the market.
For instance, according to an updated article published in January 2024, by the National Library of Medicine Addison's disease is a rare disease where the incidence is 0.6 per 100,000 of the population per year. The total number of people affected by this condition at a given time ranges from 4 to 11 per 100,000 of the population. In adults, the common age of presentation is 30 to 50 years. It is more common in women.
The rise in awareness of Addison's disease is another key factor driving the market to grow during the forecast period. General awareness about the diseases is an important key factor for every patient diagnosed with it for that purpose HCA Florida Healthcare initiated April Adrenal Disease Awareness Month and HCA Florida South Tampa Hospital is raising awareness about the diagnosis and treatment of adrenal diseases.
With increased awareness, our community will become more knowledgeable about when to consult their physician regarding testing and treatment. Adrenal Disease Awareness Month is important because increased awareness emphasizes the vital purpose of the adrenal glands and encourages the general public to seek treatment if a disorder is suspected.
According to the article "Adrenal Insufficiency in Patients," published in June 2021, it has been found that one in 10,000 newborns is affected by congenital adrenal hyperplasia, an inherited form of primary adrenal insufficiency.
Restraints
Factors such as the high costs associated with the treatment medications, the complications associated with the disease, the lack of awareness among people regarding Addison's disease, and the inability to diagnose the disease early are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The Addison’s disease market is segmented based on type, drug class, route of administration, distribution channel and region.
The primary adrenal insufficiency segment accounted for approximately 39.3% of Addison’s disease market share
The primary adrenal insufficiency segment is expected to hold the largest market share over the forecast period. Primary adrenal insufficiency is characterized by decreased aldosterone and cortisol production due to diminished gland function. It can either present acutely, which may present as an adrenal crisis, or it can be chronic, which is called Addison disease.
As per ResearchGate publication in 2023, primary adrenal insufficiency (PAI) is easy to diagnose. The challenge is to consider it as a differential diagnosis since it is rare, symptoms develop gradually, and are unspecific and common.
For instance, in February 2022, Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announced that the first patient has been dosed in its Phase 2 European clinical trial of modified-release hydrocortisone (DNL-0200 ? previously referred to as Chrono Cort for a line extension in adrenal insufficiency (AI).
Global healthcare services have shifted their resources towards COVID-19 care due to the increase in COVID-19 cases, which has an impact on patients with uncommon diseases. According to the February 2021 Eurordis International Survey, people with uncommon diseases appeared to be less fortunate than those with chronic diseases as a result of the pandemic.
Moreover, key players in the industry focusing on R&D activities and launching new products propel the market growth.
Geographical Analysis
North America accounted for approximately 42.6% of Addison’s disease market share
North America region is expected to hold the largest market share over the forecast period. The rising number of clinical trials has resulted in the development of novel treatments is seeing an increase in demand from North American regions with significant competitors like Teva Pharmaceuticals, Aspen Pharma, Pfizer Inc, Merck KGaA, and others actively operating in the market.
In this region, owing to factors such as increasing disease instances in the region, acquisition by key players, rising number of clinical trials, growing demand for new generation technologically integrated advanced therapeutic drugs for swift and long-term therapy, and a well-established healthcare infrastructure
For instance, in June 2021, Eton Pharmaceuticals, Inc., the U.S. marketer of ALKINDI SPRINKLE, a treatment for adrenocortical insufficiency in pediatric patients, announced that it has acquired U.S. and Canadian rights to Crossject’s ZENEO hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis. ZENEO is a proprietary needleless device developed and manufactured by Project.
The pre-filled, single-use device propels medication through the skin in less than a tenth of a second. The device’s compact form factor, simple two-step administration, and needle-free technology make it an ideal delivery system for emergency medications that need to be administered in stressful situations by non-healthcare professionals.
Moreover, key players in the industry strategies such as partnerships and collaborations would drive this market. For instance, in April 2022 Diurnal Group extended its distribution agreement with Er-Kim to include the distribution and marketing of Alkindi (hydrocortisone granules in capsules for opening) and Efmody (hydrocortisone modified-release hard capsule) in Greece, Cyprus, and Malta.
COVID-19 Impact Analysis
COVID-19 had a substantial impact on the global Addison’s disease market where although it is well established that intercurrent illness triggered adrenal decompensation leading to a diagnosis or worsening or primary adrenal insufficiency, this is the first description of a case in which SARS-CoV-2 infection/ COVID-19 unmasks Addison’s disease.
The study titled 'COVID-19 and the Endocrine System: Exploring the Unexplored' stated that the adrenal system is one of the most severely impacted organ systems in the body during acute active infection in persons with COVID-19 infection who require hospitalization. As a result of the outbreak, businesses and other non-healthcare industries were forced to close. This affected Addison's disease market.
The rise in COVID-19 cases has led to global healthcare services shifting their resources toward COVID-19 care while impacting patients with rare diseases. According to the Eurordis International Survey in February 2021, rare disease patients seemed to have a worse experience than chronic disease patients due to the pandemic
During the pandemic time, Addison’s self-help group press release in May 2020, Addison's Disease and Adrenal Insufficiency, at least 1785 people in the UK were unable to self-manage COVID-19 to reduce the burden on the NHS.
Market Segmentation
By Type
- Primary Adrenal Insufficiency
- Secondary Adrenal Insufficiency
- Tertiary Adrenal Insufficiency
By Drug Class
- Oral Corticosteroid
- Hydrocortisone
- Fludrocortisone
- Corticosteroid Injections
- Sodium Intake
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospitals and Clinics
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in Addison’s disease market include Teva Pharmaceuticals, Ralington Pharma, Aspen Pharma, Pfizer Inc, Merck KGaA, Anant Pharmaceuticals, Symbiotech, Curia, AuroPharma, Parchem fine & specialty chemicals among others.
Key Developments
- On March 1, 2024, Mallinckrodt plc. announced the FDA has approved supplemental New Drug Application (sNDA) for the Acthar Gel (repository corticotropin injection) single-dose pre-filled SelfJect injector, a new Acthar Gel delivery device for qualified patients with a range of acute and chronic inflammatory and autoimmune conditions.
- On June 1, 2022, ANI Pharmaceuticals, Inc. announced that the Company received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application (ANDA) for Fludrocortisone Acetate Tablets USP, 0.1 mg. ANI’s Fludrocortisone Acetate Tablets are the generic version of the Reference Listed Drug (RLD) Florinef.
- On January 18, 2022, Antares Pharma announced that the United States Food and Drug Administration had granted Fast Track designation for ATRS-1902 for adrenal crisis rescue in adults and adolescents using the company's Vai novel proprietary auto-injector platform to deliver a stable liquid formulation of hydrocortisone.

Why Purchase the Report?
- To visualize Addison’s disease market segmentation based on type, drug class, route of administration, distribution channel, end-user, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of Addison’s disease market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in excel consisting of key products of all the major players.
The Addison’s disease market report would provide approximately 70 tables, 67 figures, and 181 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. A Rise in the Prevalence & Awareness of Addison's Disease
4.1.1.2. Advancements in the Treatment of Addison's Diseases
4.1.2. Restraints
4.1.2.1. Complications Associated with the Disease
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Primary Adrenal Insufficiency *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Secondary Adrenal Insufficiency
7.4. Tertiary Adrenal Insufficiency
8. By Drug Class
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.1.2. Market Attractiveness Index, By Drug Class
8.2. Oral Corticosteroid *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Hydrocortisone
8.4. Fludrocortisone
8.5. Corticosteroid Injections
8.6. Sodium Intake
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospitals and Clinics *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. South Korea
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Teva Pharmaceuticals*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Ralington Pharma
13.3. Aspen Pharma
13.4. Pfizer Inc
13.5. Merck KGaA
13.6. Anant Pharmaceuticals
13.7. Symbiotech
13.8. Curia
13.9. AuroPharma
13.10. Parchem Fine & Specialty Chemicals
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us